News

The license agreement is expected to enable Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient

Progen Pharmaceuticals said that it had recently terminated its previous agreement with Global Transbiotech and was looking for a partner that could complete product development and commercialisation of

The investigational new drug application (IND) was reviewed through SFDA’s Green Channel expedited application process. The first patients were dosed on April 28, 2010. Sulfatinib (HMPL-012) is a

Avanir Pharmaceuticals expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval

Automaglia 90 Analyzer is a fully-automated analyzer for immunoassay analysis in various types of diseases and disorders. Major clinical diagnostic applications include thyroid disorders, fertility and infertility disorders,

The ANDA, which was developed and registered by Granules, is in collaboration with Heritage Pharmaceuticals, a generic pharmaceutical company. Under a previous agreement, Heritage retains exclusive sales and

Mnemonics said that the tool helps in inspecting multiple-page documents including batch inspection of labels, catalogs, instruction manuals, long manuscripts, magazines. Mnemonics claimed that AVIA Infinity makes proofreading

Dendreon plans to have three plants to make Provenge by mid of 2011. According to an estimate by Bloomberg the drug is expected to generate $1.2bn by 2014.

The approval is based on data from the pivotal SATURN study which showed that compared to placebo Tarceva gave patients with stable disease a 39% improvement in overall